2. Neuronal Signaling
  3. Monoamine Oxidase
  4. MDL 72527

MDL 72527 is a potent polyamine oxidase (PAO) inhibitor. MDL 72527 shows a lysosomotropic effect. MDL 72527 shows neuroprotective effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

MDL 72527

MDL 72527 Chemische Struktur

CAS. Nr. : 93565-01-6

Größe Preis Verfügbarkeit Menge
Kostenlose Probe (0.1 - 0.2 mg)   Jetzt bewerben  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 Auf Lager
Solution
10 mM * 1 mL in DMSO Auf Lager
Solid
5 mg Auf Lager
10 mg Auf Lager
25 mg Auf Lager
50 mg Auf Lager
100 mg Auf Lager
200 mg   Angebot einholen  
500 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Other Forms of MDL 72527:

MDL 72527 Related Antibodies

Top Publications Citing Use of Products

Alle Monoamine Oxidase Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen
MAO-A MAO-B

  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

Beschreibung

MDL 72527 is a potent polyamine oxidase (PAO) inhibitor. MDL 72527 shows a lysosomotropic effect. MDL 72527 shows neuroprotective effects[1][2].

IC50 & Target

polyamine oxidase (PAO)[1]
In Vitro

MDL 72527 (300 µM; 24 h) shows evident morphological changes with the appearance of a large number of lysosomes and numerous cytoplasmic vacuoles in M14 WT cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MDL 72527 Related Antibodies

Cell Cytotoxicity Assay[2]

Cell Line: M14 cells
Concentration: 300 µM
Incubation Time: 24 h
Result: Showed no significant effect on cell survival of melanoma cells.
In Vivo

MDL 72527 (100 mg/kg; i.p.; once) shows neuroprotective against neuronal cell damage after temporary focal cerebral ischemia[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 250-300 g, Male spontaneously hypertensive rats (SHRs)[1]
Dosage: 100 mg/kg
Administration: I.p.; after the induction of ischemia
Result: Significantly reduced meanarterial blood pressure, changed the brain edema formation from 85.7 ± 0.3 to 84.5 ± 0.9% in cortex and from 79.9 ± 1.7 to 78.4 ± 2.0% in subcortex (difference not significant), reduced ischemic injury volume by 22% in the cortex and 17% in the subcortex.
Molekulargewicht

265.22

Formel

C12H22Cl2N2
CAS. Nr.
Appearance

Solid

Color

White to off-white

SMILES

C=C=CCNCCCCNCC=C=C.[H]Cl.[H]Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Lösungsmittel & Löslichkeit
In Vitro: 

DMSO : 12.5 mg/mL (47.13 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.7705 mL 18.8523 mL 37.7045 mL
5 mM 0.7541 mL 3.7705 mL 7.5409 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molaritätsrechner

  • Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1.25 mg/mL (4.71 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 1.25 mg/mL (4.71 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  Saline

    Solubility: 50 mg/mL (188.52 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
Verweise

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.7705 mL 18.8523 mL 37.7045 mL 94.2614 mL
5 mM 0.7541 mL 3.7705 mL 7.5409 mL 18.8523 mL
10 mM 0.3770 mL 1.8852 mL 3.7705 mL 9.4261 mL
15 mM 0.2514 mL 1.2568 mL 2.5136 mL 6.2841 mL
20 mM 0.1885 mL 0.9426 mL 1.8852 mL 4.7131 mL
25 mM 0.1508 mL 0.7541 mL 1.5082 mL 3.7705 mL
30 mM 0.1257 mL 0.6284 mL 1.2568 mL 3.1420 mL
40 mM 0.0943 mL 0.4713 mL 0.9426 mL 2.3565 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

MDL 72527 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MDL 7252793565-01-6MDL72527MDL-72527Monoamine OxidaseMAOInhibitorinhibitorinhibit

Ihre kürzlich angesehenen Produkte:

Online-Anfrage

Your information is safe with us. * Required Fields.

Produktname

  

Requested Quantity *

Name des Antragstellers *

 

Anrede

E-Mail-Addresse *

 

Telefonnummer *

Department

 

Name der Organisation *

City

Bundesland

Country or Region *

      

Bemerkungen

Massenanfrage

Inquiry Information

Produktname:
MDL 72527
Art. -Nr.:
HY-100621
Menge:
MCE Japan Authorized Agent:

Kundenbewertung

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Produktname

  

Lot #

Name des Antragstellers *

 

E-Mail-Addresse *

Telefonnummer

 

Department *

Name der Organisation *

 

Country or Region *

Bemerkungen

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.